Uhm uhm,market cap will be above $300M before the final phase 3 results will be released in 2016. Now there is the DSMB evaluation on ZopTEc for safety and efficacy, which has three options: 1 advice to stop the trial because of lack of efficacy 2 advice to continue the trial because of sufficient safety and efficacy 3 advice for immediate FDA APPROVAL because of superior efficacy and safety
I hope you made this previous post because you didn't know that. Otherwise I will permanently delete all your Posts from now on.